Abstract P4-09-03: On the development and clinical value of RNA-sequencing-based classifiers for prediction of the five conventional breast cancer biomarkers: A report from the population-based multicenter SCAN-B study
(2018) San Antonio Breast Cancer Symposium, 2017 In Cancer research. Supplement 78(4).- Abstract
- Background:
In early breast cancer, five histopathological biomarkers are part of current clinical routines and used for determining prognosis and treatment: estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (ERBB2/HER2), Ki67, and Nottingham histological grade (NHG). We aimed to develop classifiers for these biomarkers based on tumor mRNA-sequencing (RNA-seq), compare classification performance to conventional histopathology, and test whether RNA-seq-based predictors could add value for patient risk-stratification.
Patients and Methods:
In total, 3678 breast tumors were studied. For 405 breast tumors in the training cohort, a comprehensive histopathological biomarker... (More) - Background:
In early breast cancer, five histopathological biomarkers are part of current clinical routines and used for determining prognosis and treatment: estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (ERBB2/HER2), Ki67, and Nottingham histological grade (NHG). We aimed to develop classifiers for these biomarkers based on tumor mRNA-sequencing (RNA-seq), compare classification performance to conventional histopathology, and test whether RNA-seq-based predictors could add value for patient risk-stratification.
Patients and Methods:
In total, 3678 breast tumors were studied. For 405 breast tumors in the training cohort, a comprehensive histopathological biomarker evaluation was performed by three pathology readings to estimate inter-pathologist variability on the original diagnostic slides as well as on repeat immunostains for this study, and the consensus biomarker status for all five conventional biomarkers was determined. Whole transcriptome gene expression profiling was performed by RNA-sequencing on the Illumina platform. Using RNA-seq-derived tumor gene expression data as input, single-gene classifiers (SGC) and multi-gene classifiers (MGC) were trained on the consensus pathology biomarker labels. The trained classifiers were tested on an independent prospective population-based series of 3273 primary breast cancer cases from the multicenter SCAN-B study with median 41 months follow-up (ClinicalTrials.gov identifier NCT02306096), and classifications were evaluated by agreement statistics and by Kaplan-Meier and Cox regression survival analyses.
Results:
For the histopathological evaluation, pathologist evaluation concordance was high for ER, PgR, and HER2 (average kappa values of .920, .891, and .899, respectively), but moderate for Ki67 and NHG (.734 and .581). Classification concordance between RNA-seq classifiers and histopathology for the independent 3273-cohort was similar to that within histopathology assessments, with SGCs slightly outperforming MGCs. Importantly, patients with discordant results, classified as hormone responsive (HoR+) by histopathology but non-hormone responsive by MGC, presented with significantly inferior overall survival compared to patients with concordant results. These results extended to patients with no adjuvant systemic therapy (hazard ratio, HR, 4.54; 95% confidence interval, CI, 1.42-14.5), endocrine therapy alone (HR 3.46; 95% CI, 2.01-5.95), or receiving chemotherapy (HR 2.57; 95% CI 1.13-5.86). For HoR+ cases receiving endocrine therapy alone, the MGC HoR classifier remained significant after multivariable adjustment (HR 3.14; 95% CI, 1.75-5.65).
Conclusions:
RNA-seq-based classifiers for the five key early breast cancer biomarkers were generally equivalent to conventional histopathology with regards to classification error rate. However, when benchmarked using overall survival, our RNA-seq classifiers provided added clinical value in particular for cases that are determined by histopathology to be hormone-responsive but by RNA-seq appear hormone-insensitive and have a significantly poorer outcome when treated with endocrine therapy alone
(Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/ff741a92-960f-4843-9a47-b16256015110
- author
- organization
-
- Breastcancer-genetics
- Translational Oncogenomics (research group)
- Tumor microenvironment
- Personalized Breast Cancer Treatment (research group)
- The Liquid Biopsy and Tumor Progression in Breast Cancer (research group)
- Surgery (research group)
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
- Clinical Sciences, Helsingborg
- Division of Translational Cancer Research
- Faculty office - The medical degree programme board
- Tumor Cell Biology (research group)
- Surgery (Lund)
- Breast Cancer Surgery (research group)
- Familial Breast Cancer (research group)
- EpiHealth: Epidemiology for Health
- publishing date
- 2018-02
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancer research. Supplement
- volume
- 78
- issue
- 4
- publisher
- American Association for Cancer Research Inc.
- conference name
- San Antonio Breast Cancer Symposium, 2017
- conference location
- San Antonio, United States
- conference dates
- 2017-12-05 - 2017-12-09
- ISSN
- 1538-7445
- DOI
- 10.1158/1538-7445.SABCS17-P4-09-03
- project
- Sweden Cancerome Analysis Network - Breast (SCAN-B): a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine
- language
- English
- LU publication?
- yes
- id
- ff741a92-960f-4843-9a47-b16256015110
- date added to LUP
- 2018-03-06 09:53:18
- date last changed
- 2022-05-12 08:29:13
@misc{ff741a92-960f-4843-9a47-b16256015110, abstract = {{Background:<br/><br/>In early breast cancer, five histopathological biomarkers are part of current clinical routines and used for determining prognosis and treatment: estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (ERBB2/HER2), Ki67, and Nottingham histological grade (NHG). We aimed to develop classifiers for these biomarkers based on tumor mRNA-sequencing (RNA-seq), compare classification performance to conventional histopathology, and test whether RNA-seq-based predictors could add value for patient risk-stratification.<br/><br/>Patients and Methods:<br/><br/>In total, 3678 breast tumors were studied. For 405 breast tumors in the training cohort, a comprehensive histopathological biomarker evaluation was performed by three pathology readings to estimate inter-pathologist variability on the original diagnostic slides as well as on repeat immunostains for this study, and the consensus biomarker status for all five conventional biomarkers was determined. Whole transcriptome gene expression profiling was performed by RNA-sequencing on the Illumina platform. Using RNA-seq-derived tumor gene expression data as input, single-gene classifiers (SGC) and multi-gene classifiers (MGC) were trained on the consensus pathology biomarker labels. The trained classifiers were tested on an independent prospective population-based series of 3273 primary breast cancer cases from the multicenter SCAN-B study with median 41 months follow-up (ClinicalTrials.gov identifier NCT02306096), and classifications were evaluated by agreement statistics and by Kaplan-Meier and Cox regression survival analyses.<br/><br/>Results:<br/><br/>For the histopathological evaluation, pathologist evaluation concordance was high for ER, PgR, and HER2 (average kappa values of .920, .891, and .899, respectively), but moderate for Ki67 and NHG (.734 and .581). Classification concordance between RNA-seq classifiers and histopathology for the independent 3273-cohort was similar to that within histopathology assessments, with SGCs slightly outperforming MGCs. Importantly, patients with discordant results, classified as hormone responsive (HoR+) by histopathology but non-hormone responsive by MGC, presented with significantly inferior overall survival compared to patients with concordant results. These results extended to patients with no adjuvant systemic therapy (hazard ratio, HR, 4.54; 95% confidence interval, CI, 1.42-14.5), endocrine therapy alone (HR 3.46; 95% CI, 2.01-5.95), or receiving chemotherapy (HR 2.57; 95% CI 1.13-5.86). For HoR+ cases receiving endocrine therapy alone, the MGC HoR classifier remained significant after multivariable adjustment (HR 3.14; 95% CI, 1.75-5.65).<br/><br/>Conclusions:<br/><br/>RNA-seq-based classifiers for the five key early breast cancer biomarkers were generally equivalent to conventional histopathology with regards to classification error rate. However, when benchmarked using overall survival, our RNA-seq classifiers provided added clinical value in particular for cases that are determined by histopathology to be hormone-responsive but by RNA-seq appear hormone-insensitive and have a significantly poorer outcome when treated with endocrine therapy alone<br/>}}, author = {{Brueffer, Christian and Vallon-Christersson, Johan and Grabau, Dorthe and Ehinger, Anna and Häkkinen, Jari and Hegardt, Cecilia and Malina, Janne and Chen, Yilun and Bendahl, Pär-Ola and Manjer, Jonas and Malmberg, Martin and Larsson, Christer and Loman, Niklas and Rydén, Lisa and Borg, Åke and Saal, Lao}}, issn = {{1538-7445}}, language = {{eng}}, note = {{Conference Abstract}}, number = {{4}}, publisher = {{American Association for Cancer Research Inc.}}, series = {{Cancer research. Supplement}}, title = {{Abstract P4-09-03: On the development and clinical value of RNA-sequencing-based classifiers for prediction of the five conventional breast cancer biomarkers: A report from the population-based multicenter SCAN-B study}}, url = {{http://dx.doi.org/10.1158/1538-7445.SABCS17-P4-09-03}}, doi = {{10.1158/1538-7445.SABCS17-P4-09-03}}, volume = {{78}}, year = {{2018}}, }